Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status

Human Pathology

Volumn 45, Issue 5, 2014, Pages 970-975

  Wang, Tao ^a   Hsieh, Eugene T ^a,b   Henry, Pauline ^a,c   Hanna, Wedad ^a,b   Streutker, Catherine J ^a,d   Grin, Andrea ^a,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c TORONTO EAST GENERAL HOSPITAL   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Biopsy; Concordance; Gastric carcinoma; HER2; Resection

Indexed keywords

BIOPSY; CONCORDANCE; GASTRIC CARCINOMA; HER2; RESECTION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOPSY; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 84898820405     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2013.12.010     Document Type: Article

References (13)

1. J.T. Jorgensen Targeted HER2 treatment in advanced gastric cancer Oncology 78 2010 26 33
2. Y.J. Bang, E. Van Cutsem, and A. Feyereislova et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 2010 687 697
3. M. Hofmann, O. Stoss, and D. Shi et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study Histopathol 52 2008 797 805
4. J. Yang, H. Luo, and Y. Li et al. Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens Cell Biochem Biophys 62 2012 221 228
5. S. Lee, W. Bastiaan de Boer, and S. Fermoyle et al. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections Histopathol 59 2011 832 840
6. B. Yan, E.X. Yau, and S.N. Choo et al. Dual-color HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples J Clin Pathol 64 2011 880 883
7. J. Rüschoff, W. Hanna, and M. Bilous et al. HER2 testing in gastric cancer: a practical approach Mod Pathol 25 2012 637 650
8. L.T. Greer, M. Rosman, and W.C. Mylander et al. Does breast tumor heterogeneity necessitate further immunohistochemical staining on surgical specimens? J Am Coll Surg 216 2013 239 251
9. H. Seol, H.J. Lee, and Y. Choi et al. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance Mod Pathol 25 2012 938 948
10. Y.L. Yang, Y. Fan, and R.G. Lang et al. Genetic heterogeneity of HER2 in breast cancer: impact on HER2 testing and its clinicopathologic significance Breast Cancer Res Treat 134 2012 1095 1102
11. M.C. Chang, J.L. Malowany, and J. Mazurkiewicz et al. 'Genetic heterogeneity' in HER2/neu testing by fluorescence in situ hybridization study of 2,522 cases Mod Pathol 25 2012 683 688
12. G.H. Vance, T.S. Barry, and K.J. Bloom et al. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines Arch Pathol Lab Med 133 2009 611 612
13. M. Pirrelli, M.L. Caruso, and M. Di Maggio et al. Are biopsy specimens predictive of HER2 status in gastric cancer patients? Dig Dis Sci 58 2013 397 404